Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for the year 2024. For the period, the company expects net revenue to be between $360 million and $380 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.48 USD | -0.51% | -4.18% | +11.06% |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
Apr. 23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.06% | 1.38B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.26% | 21.25B | |
-5.80% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024